跳到正文
原文
Nature Medicine· Dehui Huang·· 12 小时前AI 评分30

关于 Obinutuzumab β 在 AQP4 阳性 NMOSD 临床试验中使用安慰剂对照的讨论

Reply to: Concerns about use of placebo control in clinical trials of Obinutuzumab β for aquaporin-4 antibody positive neuromyelitis optica spectrum disorder

AI 导读

作者回应了关于 Obinutuzumab β 在 AQP4 阳性 NMOSD 临床试验中使用安慰剂对照的质疑,认为该试验未违反《赫尔辛基宣言》。研究团队强调了临床背景、方法学理由、受试者保护措施及后续随访结果。

正文
  • Matters Arising
  • Published: 20 November 2026

Nature Medicine (2026) Cite this article

replying to E. S. Sotirchos & D. Saylor Nature Medicine https://doi.org/10.1038/s41591-026-04781-0 (2026)

We thank Sotirchos and Saylor1 for raising the important question of control-group selection. We agree that neuromyelitis optica spectrum disorder (NMOSD) relapses can cause severe and irreversible neurological injury and that effective targeted therapies have changed the ethical and methodological context of subsequent trials. However, we respectfully disagree with the categorical conclusion that the BeInmost study2 violated the Declaration of Helsinki, based on the published record alone. We clarify the clinical context, methodological rationale, participant-protection measures and post hoc follow-up outcomes below.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

32.70 € / 30 days cancel any time

Learn more

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

39,95 €

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

References

  1. Sotirchos, E. S. & Saylor, D. Concerns about use of placebo control in clinical trials of Obinutuzumab β for aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Nat. Med. https://doi.org/10.1038/s41591-026-04781-0 (2026).

  2. Wu, L. et al. Obinutuzumab β for aquaporin-4-positive neuromyelitis optica spectrum disorder: a phase 3 randomized controlled trial. Nat. Med. 32, 3672–3681 https://doi.org/10.1038/s41591-026-04583-4 (2026).

  3. Beijing Mabworks Biotech Co. A study of MIL62 in patients with neuromyelitis optica spectrum disorder (NMOSD). ClinicalTrials.gov identifier: NCT05314010

  4. Wu, L. et al. Safety and efficacy of obinutuzumab β (MIL62), a novel glycoengineered type II anti-CD20 monoclonal antibody, in patients with neuromyelitis optica spectrum disorder: a multicenter, single-arm, phase Ib clinical trial. Neurol. Ther. 15, 1845–1862 https://doi.org/10.1007/s40120-026-00960-w (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Satralizumab injection: Chinese prescribing information. Approved 30 April 2021. https://assets.roche.com/f/249469/x/2643675ae3/satelizhudankangzhusheye_20210508.pdf (in Chinese) (Roche, 2021).

  6. Inebilizumab injection: Chinese prescribing information. Approved 8 March 2022; revised 20 September 2022. https://cn.hspharm.com/upload/file/2023/03/07/68aa912d3168446b861652f2bf2eb8d2.pdf (in Chinese) (Horizon Therapeutics Ireland DAC, 2022).

  7. Shanghai Roche Pharmaceuticals. Satralizumab injection: application materials for the 2023 National Reimbursement Drug List adjustment (public version), 3 (in Chinese). https://www.nhsa.gov.cn/attach/Ypsn2023/YPSW202300315/YPSW202300315-W1,W5.pdf (China Healthcare Security, 2023).

  8. Drug price information: satralizumab injection, 120 mg/1 ml, CNY 11,318 per syringe (in Chinese). https://www.ynpfph.cn/info/y/0p20.html (The First People’s Hospital of Yunnan Province, 14 October 2024).

  9. Households’ income and consumption expenditure in 2024. https://www.stats.gov.cn/sj/zxfb/202501/t20250117_1958325.html (in Chinese) (National Bureau of Statistics of China, 17 January 2025).

  10. Xu, Y. Interpretation of the MS/NMOSD sociological survey white paper. Presentation at the launch meeting and standards release for the MS/NMOSD center development project, Beijing, China, 24 December 2023 (recorded conference presentation; in Chinese) (China Alliance for Rare Diseases, 2023).

  11. Yu, Y., Zhong, M., Quan, C. & Ma, C. Treatment access and satisfaction on disease-modifying therapies of neuromyelitis optica spectrum disorder patients in China: a cross-sectional survey. Ther. Adv. Neurol. Disord. 17, 17562864241239105 https://doi.org/10.1177/17562864241239105 (2024).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. 2025 White Paper on the Disease Burden Of Patients with Neuromyelitis Optica Spectrum Disorder in China (in Chinese) (Center for Pharmaceutical Policy and Economics Research, School of Pharmaceutical Science and Technology, Tianjin University & Duoshen Jiayuan, 2025).

  13. Choice of Control Group and Related Issues in Clinical Trials. ICH Harmonised Tripartite Guideline E10. https://database.ich.org/sites/default/files/E10_Guideline.pdf (ICH, 2000).

  14. Pittock, S. J. et al. Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Ann. Neurol. 93, 1053–1068 https://doi.org/10.1002/ana.26626 (2023).

    Article  PubMed  CAS  Google Scholar 

  15. Obinutuzumab beta injection: prescribing information. Approved 10 February 2026. https://www.mab-works.com/uploads/ueditor/file/20260311/1773211773625564.pdf (in Chinese) (Beijing Mabworks Biotech Co., 2026).

  16. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310, 2191–2194 https://doi.org/10.1001/jama.2013.281053 (2013).

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, The First Medical Center of Chinese PLA General Hospital, Beijing, China

    Dehui Huang & Lei Wu

  2. Beijing Mabworks Biotech Co., Ltd., Beijing, China

    Feng Li & Min Wei

  3. Department of Neurology, Yuebei People’s Hospital Affiliated to Shantou University Medical College, Shaoguan, China

    Junbin Chen

Authors

  1. Dehui Huang
  2. Lei Wu
  3. Feng Li
  4. Junbin Chen
  5. Min Wei

Contributions

M.W. prepared the initial draft. D.H., L.W., F.L. and J.C. contributed to the clinical, methodological and regulatory interpretation and critically revised the response. All authors approved the final version and agree to be accountable for the work.

Corresponding author

Correspondence to Dehui Huang.

Ethics declarations

Competing interests

F.L. and M.W. are employees of Beijing Mabworks Biotech Co. Ltd., the sponsor of the BeInmost trial. D.H., L.W. and J.C. declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, D., Wu, L., Li, F. et al. Reply to: Concerns about use of placebo control in clinical trials of Obinutuzumab β for aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Nat Med (2026). https://doi.org/10.1038/s41591-026-04782-z

Download citation

  • Received: 25 October 2026

  • Accepted: 26 October 2026

  • Published: 20 November 2026

  • Version of record: 20 November 2026

  • DOI: https://doi.org/10.1038/s41591-026-04782-z

来源:Nature Medicine · nature.com